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Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) belong to the most frequently used drugs.
The discovery of an inducible isoform of cyclo-oxygenase (COX-2) has led to an intensive
worldwide search and the introduction of selective COX-2 inhibitors. In this review, recent
advances in understanding the mechanism of action of NSAIDs and, in this context, clinical
findings on NSAID-induced gastrointestinal side effects are summarized. This knowledge is
important for the effective treatment of pain and inflammation, as well as for preventing
serious and sometimes lethal gastrointestinal side effects.
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Introduction
With a total of 97 million prescriptions per year in
Germany alone, analgesic and anti-rheumatic drugs are
the foremost medication in terms of frequency of use.
Every day they are taken by more than 30 million people
worldwide; of these, 40% of consumers are older than 60.
Only 4.5% of the prescriptions are for so-called centrally
acting analgesics, namely the opioids. Population studies
have shown that 10–20% of all people who are 65 years
or older either are currently receiving or have recently
received a prescription for nonsteroidal antirheumatic
drugs. During the next 20 years the number of people over
65 is expected to increase from 380 million to 600 million.
The very frequent use of NSAIDs is based on the fact that
these agents have many indications for which a large
number of patients exist. These indications include chronic
polyarthritis, psoriatic arthritis, ankylosing spondylitis,
osteoarthritis, gout, inflammatory soft tissue rheumatism,
low back pain, postoperative and post-traumatic inflamma-
tion, thrombophlebitis and vasculitis.
The history of analgesic and anti-inflammatory substances
started with the use of decocted salicylate-containing
plants by ancient Greek and Roman physicians. Willow
bark was already mentioned in the Corpus Hippocraticum
(a collection of medical scripts compiled by Alexandrian
scholars in approximately 300 BC) as a substance for treat-
ing fever and pain conditions. Over the past 140 years other
substances have been introduced for therapy, collectively
termed nonsteroidal anti-inflammatory drugs (NSAIDs),
after PS Hench discovered the anti-inflammatory properties
of glucocorticoids in 1949. NSAIDs, which possessArthritis Research    Vol 2 No 5 Steinmeyer
analgesic, anti-inflammatory and antipyretic properties, are
a heterogeneous group of substances without any uniform
chemical properties (although most are organic acids), but
nevertheless share the same therapeutic and side effects.
In the past few years there have been significant advances
in explaining the mechanism of action of NSAIDs.
Mechanism of action of NSAIDs
In the 1930s, Goldblatt and von Euler showed that human
seminal fluid contained a component that reduced blood
pressure, the effects of which could not be classified
among the tissue hormones known at the time. Von Euler
termed these new, unknown substances ‘prostaglandins’
because he presumed that these mediators were pro-
duced in the prostate [1,2]. After Bergström and Sjövall
achieved the first chemical identification of a prosta-
glandin at the beginning of the 1960s, the era of prosta-
glandin research began [3]. It turned out that these
hormones could be synthesized by many mammalian cells
and that they participate in the regulation of numerous
physiological functions.
Another milestone was the discovery by Vane and co-
workers that the analgesic, antipyretic and anti-inflamma-
tory properties of acetylsalicylate were based on the
inhibition of prostaglandin synthesis [4]. Vane showed that
the acidic anti-inflammatory analgesics decreased pro-
inflammatory prostaglandin concentrations by inhibiting
cyclo-oxygenase. This finding made sense because the
prostaglandins characterized in the 1960s were found to
be substantially involved in bringing about and maintaining
inflammatory processes by increasing vascular permeabil-
ity and amplifying the effects of other inflammatory media-
tors such as kinins, serotonin and histamine. Prostaglandin
E2 (PGE2) is also involved in the induction of fever. As we
now know, prostaglandins are not themselves significant
mediators of pain; instead, they increase the sensitivity of
nociceptors to other stimuli in traumatized tissue. They
switch normally non-excitable polymodal receptors (‘silent
nociceptors’) into a state in which they are easily excitable.
The biosynthesis of prostaglandins
Cyclo-oxygenase, also known as prostaglandin H synthase
(PGH synthase), catalyzes the conversion of arachidonic
acid (hydrolytically liberated from membrane phospholipids)
to the prostaglandin endoperoxides PGG2 and PGH2, with
the addition of two oxygen molecules. In this pathway two
reaction steps can be differentiated, catalyzed by different
domains of the cyclo-oxygenase protein. The first is the
cyclo-oxygenase reaction (in which the formation of a C5
ring system occurs, leading to the formation of PGG2), and
the second is the peroxidase reaction (in which the peroxide
group at C-15 is reduced to an alcohol with the formation of
PGH2). PGH2 is the precursor for the biologically active
prostaglandins and thromboxanes. NSAIDs inhibit only the
cyclo-oxygenase reaction of the PGH synthase.
Physiology and pathophysiology of prostaglandins
Prostaglandins are formed in numerous types of cell within
an organism. Their effects are complex and depend on the
type of target cells, among other factors. For this reason it
is difficult to generalize the physiological roles of individual
prostaglandins, because the same compound can some-
times exert even opposite effects on different types of
target cell. Prostaglandins are important in the regulation
of thrombocyte aggregation, inflammatory processes, pain
and fever induction, the regulation of vessel perfusion, and
many other processes. From these properties one can
deduce the spectrum of activity of prostaglandin biosyn-
thesis inhibitors such as indomethacin, ibuprofen and
acetyl salicylic acid: NSAIDs function as anti-inflammatory,
antipyretic and analgesic substances. According to the
mechanism of action put forward by Vane, the unwanted
side effects of NSAIDs can also be explained [eg erosion
and bleeding in the gastrointestinal (GI) tract, kidney func-
tion disorders, disturbance of blood coagulation], which
arise from a blockade of the physiological effects of
prostacyclin, PGE2 and thromboxane A2 (Fig. 1). In this
way, the ulcerogenic activity of NSAIDs can be derived
from the physiological functions of PGE2 and prostacyclin.
Both tissue hormones are cytoprotective towards the
stomach: they stimulate the production of mucus and
inhibit acid secretion. NSAIDs inhibit endogenous
prostaglandin synthesis and in this way remove this cyto-
protective effect; thus, the induction of ulcers is promoted.
Pharmacokinetic effects on the mechanism of action
Accumulation of the acid nonsteroidal anti-inflammatory/
analgesic compounds occurs particularly in inflamed
tissue, in the GI mucosa, in the renal cortex, in the blood
and in bone marrow owing to their acidic nature (pKa
3–5.5) and their high capacity for binding proteins (more
than 90%) [5–7]. This property is considered to be a deci-
sive factor not just for their anti-inflammatory properties but
also for the previously mentioned unwanted effects of
these substances. In chronically inflamed pulmonary tissue,
NSAIDs lead to an increased production of leukotrienes
and in this way to asthma-like reactions due to the inhibi-
tion of prostaglandin synthesis [8]. With non-acid, neutral
(paracetamol) or weakly basic (phenazone and derivatives)
analgesics that do not accumulate in damaged tissue [9]
but reach relatively high concentrations in the central
nervous system, such side effects are either not noticed or
are only marginally so. Consistent with these findings are
observations that paracetamol and phenazone are only
weak inhibitors of prostaglandin synthesis in the periphery
[4,10], whereas paracetamol interferes with prostaglandin
synthesis in the central nervous system [11].
NSAIDs as inhibitors of cyclo-oxygenase-1 and cyclo-
oxygenase-2
In 1990, the first evidence for the existence of an inducible
isoform of cyclo-oxygenase (COX) was published by thehttp://arthritis-research.com/content/2/5/379
group of P Needleman [12,13]. Structural analysis showed
that the isoenzymes COX-1 and COX-2 had an amino acid
sequence homology of approximately 60%. However, the
isoforms encoded by different genes differ in their tissue
distributions and regulation of expression. COX-1 is
expressed constitutively in almost all cell types, including
thrombocytes and those present in kidney, stomach and
vascular endothelium, and is synthesized and regulated as a
so-called ‘housekeeping enzyme’ involved in physiological
adaptation (Fig. 1). COX-2 in contrast is inducible; induction
can occur during tissue damage or inflammation in
response to cytokines (tumour necrosis factor-a,
interleukin-1), mitogens and growth factors. The induction of
COX-2 has been observed in macrophages and mono-
cytes, endothelial cells, chondrocytes and osteoblasts. An
increased COX-2 level has also been registered in the syn-
ovial tissue of patients with rheumatoid arthritis and
osteoarthritis [14]. These first findings led to the hypothesis
(Fig. 2) that a selective blockade of the COX-2 isoform
should lead to the inhibition of inflammation and pain
without impeding the COX-1-dependent effects in the GI
tissue and kidney, and in blood coagulation [16]. This
hypothesis led to an intensive worldwide search for selec-
tive COX-2 inhibitors; since 1999 rofecoxib (Vioxx®) and
celecoxib (Celebrex®) have been available on the markets.
In the quest for selective COX-2 inhibitors, a number of
established NSAIDs (etodolac, meloxicam, nabumetone)
rather surprisingly showed a seemingly selective inhibition
of COX-2 [17–19]. However, further studies revealed that
the COX-1–COX-2 selectivity of a test substance varied
significantly depending on the test system (isolated
enzymes, cell homogenates, cell lines or isolated cells) and
the experimental conditions (incubation time or stimulus
used). The full blood assay described by Patrono and co-
workers [20] has proved to be a valuable method for deter-
mining the COX-1–COX-2 selectivity of a compound in
clinically relevant human blood cells (thrombocytes and
monocytes). Studies with this new assay have finally shown
that none of the NSAIDs used previously selectively inhib-
ited COX-2, in other words under therapeutic conditions it
allowed thrombocyte aggregation and thromboxane syn-
thase to be kept intact while the formation of PGE2 after an
inflammatory stimulus was suppressed. Some substances
(diclofenac-Na, meloxicam and nimesulide) can at best be
described as ‘preferential’ inhibitors of COX-2. Because
the COX inhibitor concentrations were determined in the
1970s and 1980s primarily on preparations containing
COX-1 (eg sheep seminal vesicle microsomes), we now
have a rather late explanation of why the NSAID plasma
level required to achieve an anti-inflammatory effect is far
greater than that required to inhibit COX in vitro.
Figure 1
Regulation of prostaglandin biosynthesis by cyclo-oxygenase-1 and cyclo-oxygenase-2 [16].
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Physiological and pathophysiological functions of cyclo-oxygenase-2.
Modified according to [15].
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COX-2 inhibitorRecent findings on the physiological and
pathophysiological role of COX-2
According to recent studies, the simple concept that
COX-2 is exclusively a pro-inflammatory enzyme can no
longer be considered valid [21,22]. Such studies have
shown that COX-2 is constitutively expressed in brain and
spinal cord, for example (Fig. 2). COX-2 is also expressed
at different time points during early pregnancy within the
mouse uterine epithelium: the enzyme has a role both in
angiogenesis (required to build up the placenta) and nida-
tion (of the fertilized eggs) [23]; the use of COX-2
inhibitors is contraindicated in pregnancy. COX-2 is also
expressed during wound healing and has been found at
the base of ulcer wounds. In this way, COX-2 inhibitors
can delay the healing of ulcers and might therefore be
unsuitable for patients with pre-existing ulcers [24]. Exper-
iments on animals have shown a delay in wound healing,
possibly due to an inhibition of angiogenesis associated
with COX-2-induced effects on growth factors [25]. A
potential clinical relevance here might be the use of selec-
tive COX-2 inhibitors for treating postoperative pain.
Numerous recent findings suggest that selective COX-2
inhibitors might open up a wide spectrum of new indica-
tions for NSAIDs. The degeneration of large areas of the
brain in Alzheimer’s disease is supposed to occur with
the involvement of COX-2 [26]. Selective COX-2
inhibitors might also be directed towards the therapy of
colorectal carcinomas [27], whereas other results show
that gastric and breast carcinomas also show increased
expression rates of COX-2 [28,29], so that selective
COX-2 inhibitors might also be therapeutically useful for
treating those tumours [30]. Recently the US FDA
approved celecoxib for the treatment of the potentially
life-threatening and rare genetic disorder called familial
adenomatous polyposis. Animal experiments have shown
that COX-2 inhibitors decelerate angiogenesis and
tumour growth in a dose dependent manner [31]. Here,
COX-2 seems to be expressed primarily in the newly
created blood vessels (especially in the endothelial cells)
needed for tumour growth.
GI side effects of NSAIDs
COX-2-selective NSAIDs were developed with the inten-
tion of reducing the unwanted side effects of NSAIDs, par-
ticularly those relating to the GI system. NSAIDs that are
not COX-2 selective produce GI side effects in between
20% and 40% of all individuals who take them. The extent
of this disease, known as NSAID-gastropathy, varies con-
siderably from asymptomatic mucosal damage that is
detectable only with an endoscope, through gastric pain,
heartburn and dyspepsia, to life-threatening, bleeding,
gastric or duodenal ulcers. Older women are more predis-
posed than older men towards developing an NSAID-
induced ulcer, in which the stomach is more often involved
than the duodenum. Here it must be emphasized that
anamnestic, symptomatic and endoscopic findings are
only moderately correlated [32]. In more than 10–20% of
patients, the first manifestation of an NSAID gastropathy
can be a severe GI complication [33].
Short-term studies (several weeks) have demonstrated that
asymptomatic mucosal damage is initially shown in up to
80% of patients after NSAID therapy [34]. The incidence
of more serious GI complications is approximately 1–2%
per year [35]. Unwanted effects in the lower GI tract
(bleeding, perforation or strictures) are rarer [36]. Approxi-
mately 10–20% of NSAID-treated patients report dyspep-
tic complaints [37]; approximately 10% interrupt therapy
within half a year because of these side effects. With con-
tinuous consumption of NSAIDs, 15–20% of the treated
patients get an ulcer [35,36], and between 1% and 3% of
continuously treated NSAID patients have to receive hospi-
tal treatment for GI bleeding or perforation. As a result of
NSAID-induced gastric ulceration, bleeding or perforation,
approximately 150000 hospital days, at a cost of 64
million, are spent each year in just one nation (Germany)
[38]. Adding the expenses for hospital treatment to the
costs of the simultaneously prescribed gastroprotective
drugs, the annual cost in Germany is approximately 128
million, purely for patients with legal health insurance [38].
In one study based on results from the large United States
databank ARAMIS, the risk of a severe GI complication is
increased 5.5-fold by therapy with NSAID [39]. At present
it is estimated that in Germany up to 2000 patients per
year bleed to death after NSAID therapy. However, this
number is probably an underestimate because these
results were derived only from patients with legal health
insurance [38]. For comparison, 814 patients died in 1997
in Germany as the consequence of infection with HIV, or
1512 persons in motor accidents [40]. These data fit well
with the conservative estimations from Great Britain with
an estimated 12000 hospital treatments and approximately
4000 deaths [41,42]. Estimations for the USA go from
more than 70000 hospital treatments and over 16000
NSAID-induced deaths [43]. In this context, the conclusion
published by A Herxheimer certainly rings true, that
patients for whom NSAIDs are prescribed are not ade-
quately informed about the symptoms of a possible GI
complication (such as upper abdominal pain and tarry
stools). When such complications occur, patients often fail
to interrupt taking the medication in time, or they consult a
physician too late [44].
Risk factors
Various studies have identified the following risk factors for
NSAID-induced GI side effects that can in part be brought
into the planning of prophylaxis: simultaneous corticos-
teroid therapy, earlier GI side effects, high dosage and long
duration of NSAID therapy, advanced patient age, alco-
holism, handicaps, and simultaneous anticoagulant
therapy. When these risk factors are present, the indication
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appropriate, a prophylactic medication should be consid-
ered. First an attempt should be made, and not merely with
older patients, to achieve the therapeutic goals with a mini-
mally gastrotoxic analgesic, such as paracetamol, or to try a
lower dose of NSAID. The use of COX-2-selective drugs
such as rofecoxib and celecoxib also seems to be a safer
option than using other NSAIDs in these risk groups.
However, one limitation is that COX-2 might also have a
role in healing ulcers of the stomach, and for this reason
caution must be exercised in patients with a previous
history of ulcer disease. It must also be emphasized that
patients infected with Helicobacter pylori seem not to rep-
resent a risk group, and the eradication of H. pylori does
not represent a safe form of prophylaxis [45].
Comparison of the GI side effects of different NSAIDs
The various NSAID substance groups induce GI side
effects to widely varying extents. However, a basic
problem in studying this is the comparability of the doses
used. According to the results of various studies, one can
presume that the ability of NSAIDs to induce GI side effects
agrees with the following general ranking scheme:
rofecoxib=celecoxib <ibuprofen <meloxicam <diclofenac-
Na <naproxen <piroxicam <indomethacin <ketoprofen, in
increasing order of activity [39,46–53]. However, at the low
doses that this comparison is based on, ibuprofen displays
primarily only analgesic effects. The results of several
studies have also shown that meloxicam belongs to the
less gastrotoxic NSAIDs. This applies especially for the
low dose of 7.5mg, which seems to have a similar effec-
tiveness to 100mg of diclofenac, or 20mg of piroxicam
[52,53]. In many cases, however, rheumatic patients
require a higher dose; with increasing doses, gastrotoxic
effects can start to appear more frequently [54]. This
agrees with the fact that COX-2 selectivity decreases with
higher doses of meloxicam [55].
Prophylaxis of an NSAID gastropathy
GI side effects of NSAIDs cannot be avoided when they
are applied as a suppository or in intramuscular or intra-
venous formulations, because the inhibition of
prostaglandin synthesis in the stomach proceeds primarily
via the systemic route [56]. Several medication-related
measures for preventing an NSAID gastropathy have been
investigated in prospective studies. However, in compar-
ing the study results one must observe the importance of
the side effects. For patients, the subjective compatibility
of the medication is the most important factor, but from a
physician’s point of view it is also important to prevent
serious, and possibly even fatal, GI complications.
Antacids and H2-receptor antagonists (eg ranitidine) are
very effective at relieving subjective complaints, but they
cannot prevent severe GI complications [35]. With the
proton pump inhibitor omeprazole, in contrast, common GI
complications can often be inhibited, although higher
doses are not necessarily more effective. In addition, not
only can the synthetic PGE1 analogue misoprostol given
prophylactically for between 4 and 6 weeks reduce
asymptomatic lesions by 90% [57] but it can also reduce
ulcer bleeding by 40%, as the MUCOSA study demon-
strated [58]. However, the application of misoprostol often
seems to be badly tolerated owing to the appearance of
diarrhoea and abdominal pain: the discontinuation rate is
high. An extensive cost–benefit analysis on the prophylaxis
of NSAID gastropathy with misoprostol revealed that this
form of prophylaxis can only be clearly recommended in
high-risk patients [59]. Studies from different industrial
countries show that almost a quarter of all patients aged
between 60 and 65 years that received an NSAID also
simultaneously received gastroprotective drugs such as
H2-receptor antagonists, proton pump inhibitors, miso-
prostol or antacids. In Great Britain the prescription rate of
these drugs is approximately 20%, in Canada 25%, in
France 34% and in Germany 28% [38,60]. In comparison
with the use of COX-2 inhibitors the place of this strategy
in therapy is difficult to predict and will possibly depend
on price. As has always been the case, NSAID therapy,
even with COX-2-selective inhibitors, should be discontin-
ued with bleeding ulcers as a matter of principle. How
long such a discontinuation should be done has not yet
been investigated systematically.
Conclusion
The development of COX-2-selective inhibitors has
already been praised with headlines such as ‘super
aspirin’ or the ‘drug of the next century’, because the first
clinical findings revealed the appearance of significantly
fewer serious GI side effects. In comparison with other
NSAIDs, a similarly strong analgesic and possibly also an
anti-inflammatory effect can be achieved [46,47,49–51,
61–64]. However, the future might not look quite as satis-
fying as at first imagined, because it has become apparent
that COX-2 does not simply have a significant role in pain
and inflammation: it also has physiological functions in
other organs. Furthermore, patient collectives in clinical
studies are not always representative, because risk groups
such as older patients or probands with chronic or GI con-
ditions are normally excluded. In this way, side effects can
appear in everyday life that are not observed in clinical
studies. An excessive COX-2 selectivity, especially when
the dose is increased, might also work disadvantageously.
An important task for medical institutions will therefore be
to report on the effectiveness and side-effect profile of
COX-2 inhibitors in comparison with NSAIDs that have
previously been used successfully, and especially in long-
term studies. Overall, however, despite the theoretically
imaginable side effects, the preliminary clinical findings are
positive. Selective COX-2 inhibitors are without question
an innovative pharmaceutical development that might have
a considerable spectrum of use.
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